Abstract
1 Nomifensine (8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline) is a new antidepressant which displays an interesting pharmacological profile and acts as a potent dopaminergic agonist.
2 In a double-blind clinical trial nomifensine was compared with a standard and widely tested antidepressant amitriptyline. A total of 24 patients with primary acute depressions, defined by research criteria, were treated for 8 weeks and their clinical condition and laboratory values monitored at regular intervals. The dosage schedule was a flexible one, with a daily dose range from 50-200 mg for nomifensine and 50-225 mg for amitriptyline.
3 Nomifensine and amitriptyline were found to be equivalent in their antidepressant efficacy. Nomifensine, however, showed a trend towards more rapid effect and was relatively free of side-effects.
4 As nomifensine combined antidepressant activity with low frequency of adverse effects, it would seem to be suitable for wider use in the treatment of primary depressions. The results of our study have to be generalized with caution because of the limited sample size.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angst J., Koukkou M., Bleuler-Herzog M., Martens H. Ergebnisse eines offenen und eines Doppelblindversuches von Nomifensin im Vergleich zu Imipramin. Arch Psychiatr Nervenkr (1970) 1974;219(3):265–276. doi: 10.1007/BF00342052. [DOI] [PubMed] [Google Scholar]
- Costall B., Kelly D. M., Naylor R. J. Nomifensine: a potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia. 1975;41(2):153–164. doi: 10.1007/BF00421073. [DOI] [PubMed] [Google Scholar]
- Feighner J. P., Robins E., Guze S. B., Woodruff R. A., Jr, Winokur G., Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972 Jan;26(1):57–63. doi: 10.1001/archpsyc.1972.01750190059011. [DOI] [PubMed] [Google Scholar]
- Hunt P., Kannengiesser M., Raynaud J. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol. 1974 May;26(5):370–371. doi: 10.1111/j.2042-7158.1974.tb09294.x. [DOI] [PubMed] [Google Scholar]
- Pecknold J. C., Ban T. A., Lehmann H. E., Klingner A. A clinical trial with nomifensin, a new antidepressant drug. Int J Clin Pharmacol Biopharm. 1975 Jun;11(4):304–308. [PubMed] [Google Scholar]
- Vereczkey L., Bianchetti G., Garattini S., Morselli P. L. Pharmacokinetics of nomifensine in man. Psychopharmacologia. 1975 Dec 31;45(2):225–227. doi: 10.1007/BF00429065. [DOI] [PubMed] [Google Scholar]